Abstract
Following FDA approval in 2018, consensus guidelines recommend andexanet alfa as first-line therapy for the management of life-threatening or uncontrollable bleeding in patients taking oral factor Xa (FXa) inhibitors. Dosing is based on the specific FXa inhibitor and dose, and the time elapsed since the patient’s last administration of the medication. Additionally, at our institution, anti-FXa screens and drug-specific assays are obtained to guide subsequent dosing based on institution protocol. The objective of this study was to evaluate andexanet alfa utilization based on anti-Xa and FXa-inhibitor-specific assays and assess associated outcomes. This was a retrospective, single-center study aimed to describe the use of anti-FXa and specific direct oral anticoagulant assays to guide the utilization and administration of andexanet alfa. Secondary endpoints evaluated included thrombotic events during index hospitalization, hospital length of stay, hospital mortality, and discharge disposition. Overall, most patients were prescribed apixaban for atrial fibrillation and received andexanet alfa for reversal of intracranial hemorrhage in the emergency department. In general, DOAC-specific assays were concordant with last known times; however, there appears to be minimal correlation with DOAC-specific assay levels and survival. There were 9 thrombotic events (8.7%) in 8 patients. In this cohort, collection of an anti-FXa assay screen was a practical strategy to guide reversal with andexanet alfa; however, the addition of DOAC-specific assay levels may not enhance clinical utility.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Not applicable.
References
Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315–352. https://doi.org/10.1016/j.chest.2015.11.026
January CT, Wann LS, Calkins H et al (2019) 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart R. J Am Coll Cardiol 74(1):104–132. https://doi.org/10.1016/j.jacc.2019.01.011
Frontera JA, Lewin JJ, Rabinstein AA et al (2016) Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine. Neurocrit Care 24(1):6–46. https://doi.org/10.1007/s12028-015-0222-x
Connolly SJ, Crowther M, Eikelboom JW et al (2019) Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. New Engl J Med 380(14):1326–1335. https://doi.org/10.1056/nejmoa1814051
Connolly SJ, Milling TJ, Eikelboom JW et al (2016) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375(12):1131–1141. https://doi.org/10.1056/nejmoa1607887
Portola Pharmaceuticals I. Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo). Published online 2018.
Tomaselli GF, Mahaffey KW, Cuker A et al (2020) 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 76(5):594–622. https://doi.org/10.1016/j.jacc.2020.04.053
Vestal ML, Hodulik K, Mando-Vandrick J et al (2022) Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. J Thromb Thrombolysis 53(1):167–175. https://doi.org/10.1007/s11239-021-02495-3
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381. https://doi.org/10.1016/j.jbi.2008.08.010
Harris PA, Taylor R, Minor BL et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform. https://doi.org/10.1016/j.jbi.2019.103208
Cuker A, Burnett A, Triller D et al (2019) Reversal of direct oral anticoagulants: guidance from the anticoagulation forum. Am J Hematol 94(6):697–709. https://doi.org/10.1002/ajh.25475
Morton C, Lista A, Jakowenko N, Salazar E, Donahue KR (2022) Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series. J Thromb Thrombolysis 53(1):235–239. https://doi.org/10.1007/s11239-021-02521-4
Acknowledgements
Thomas Ortel, MD, PhD; Maria Notini.
Funding
Not applicable.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
HL, WV, MV, IW, and BK have no relevant conflicts of interests to disclose.
Ethical approval
IRB-approved.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Lanham, H.T., Viriyakitja, W., Vestal, M. et al. Characterization of an andexanet alfa administration protocol guided by drug-specific quantitative anti-Xa assays. J Thromb Thrombolysis 57, 285–292 (2024). https://doi.org/10.1007/s11239-023-02899-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-023-02899-3